Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
HH.2.1NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
HH.2.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
HH.2.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XCENUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
XCENUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
XCENUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XCENUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XCENUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22756US
XCENUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
XCENSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XCENSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HN.4.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
HN.4.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
HN.4.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HN.4.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
HN.4.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
HN.4.1NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
HN.4.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
HN.4.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GU.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
GU.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
GU.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GU.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GU.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
GU.1NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
GU.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
GU.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GQ.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
GQ.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
GQ.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GQ.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GQ.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
GQ.1NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
GQ.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
GQ.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JA.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
JA.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
JA.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JA.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JA.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
JA.1NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
JA.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
JA.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.5.1.10NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
EG.5.1.10NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
EG.5.1.10NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EG.5.1.10NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
EG.5.1.10NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
EG.5.1.10NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
EG.5.1.10NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used